https://www.marketscreener.com/quote/stock/BIOCON-LIMITED-9059261/news/Biocon-Presented-Insights-into-Clinical-Study-That-Enabled-DCGI-Approval-of-Itolizumab-for-COVID-1-30921629/?utm_source=telegram&utm_medium=social&utm_campaign=share